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Technological advances now allow us to rapidly produce CARs and other antibody-derived
therapeutics targeting cell surface receptors.To maximize the potential of these new tech-
nologies, relevant extracellular targets must be identified.The Pediatric Oncology Branch of
the NCI curates a freely accessible database of gene expression data for both pediatric can-
cers and normal tissues, through which we have defined discrete sets of over-expressed
transcripts in 12 pediatric cancer subtypes as compared to normal tissues. We coupled
gene expression profiles to current annotation databases (i.e., Affymetrix, Gene Ontology,
Entrez Gene), in order to categorize transcripts by their sub-cellular location. In this manner
we generated a list of potential immune targets expressed on the cell surface, ranked by
their difference from normal tissue. Global differences from normal between each of the
pediatric tumor types studied varied, indicating that some malignancies expressed tran-
script sets that were more highly diverged from normal tissues than others.The validity of
our approach is seen by our findings for pre-B cell ALL, where targets currently in clinical tri-
als were top-ranked hits (CD19, CD22). For some cancers, reagents already in development
could potentially be applied to a new disease class, as exemplified by CD30 expression on
sarcomas. Moreover, several potential new targets shared among several pediatric solid
tumors are herein identified, such as MCAM (MUC18), metadherin (MTDH), and glypican-2
(GPC2). These targets have been identified at the mRNA level and are yet to be validated
at the protein level.The safety of targeting these antigens has yet to be demonstrated and
therefore the identified transcripts should be considered preliminary candidates for new
CAR and therapeutic antibody targets. Prospective candidate targets will be evaluated by
proteomic analysis including Westerns and immunohistochemistry of normal and tumor
tissues.
Keywords: cancer antigens, rhabdomyosarcoma, Ewing’s sarcoma, osteosarcoma, hepatoblastoma, glioblastoma,
neuroblastoma, sarcoma
INTRODUCTION
“Tumor-associated antigens” are multi-faceted and can be defined
as any entity that the immune system can avail itself of to pro-
tect the host from disease. Virus-encoded tumor antigens are
currently being targeted by preventive vaccines, such as for papil-
loma viruses, or by adoptive immunotherapy, as in EBV-associated
post-transplant lymphoma. Self-antigens presented on major his-
tocompatibility antigens (MHC) molecules are also key to clearing
disease by donor-derived cells in the context of bone-marrow
or hematopoietic stem cell transplantation (HSCT; Miller et al.,
2010). However, with the advent of antibody-based therapies,
cell-surface antigens on tumor cells can be targeted without first
requiring processing and presentation by the MHC. Thus, a tumor
antigen may be a unique molecule expressed by a tumor that is not
encoded by the healthy genome, a non-mutated developmental
antigen now re-expressed on a tumor cell, or a self-antigen than
can be safely targeted without loss of host integrity. One example
of recent interest is the re-expression of the developmentally reg-
ulated ALK protein on neuroblastoma (Mosse et al., 2008). The
work we present here indicates that there are other such targets
that remain to be discovered.
Our goal was to develop a method for identifying tumor antigen
candidates that could be targeted by antibody or CAR-based ther-
apies by leveraging publically available microarray gene expression
databases of pediatric cancer. Previously we explored a series of
established xenograft cell lines from pediatric cancers in support
of the Pediatric Oncology Pre-clinical Protein-Tissue Array Project
(POPP-TAP), a project jointly supported by the Children’s Oncol-
ogy Group and the NCI (Whiteford et al., 2007). In analyzing these
xenograft models we also began to assemble comparator normal
tissue databases1 (“Pediatric Xenograft & Tumor Gene Expres-
sion Database”). This earlier study was carried out using a gene
expression array from Research Genetics (Huntsville, AL, USA).
These studies were expanded to include normal tissue analysis on
the commonly available Affymetrix platform (“Pediatric Tumor
1http://pob.abcc.ncifcrf.gov/cgi-bin/JK
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Affymetrix Database” at see text footnote 1), allowing for easier
comparison to analyses from other groups (Chen et al., 2008).
Averaging gene expression levels from individual tumor samples
according to diagnostic category, and comparing this expression
level transcript by transcript to average normal tissue expres-
sion levels, allowed a statistical measure of the difference of that
transcripts expression from its expression in normal tissue. Rank-
ing the identified transcripts, and then filtering them for plasma
membrane expression is a first step in the high-throughput identi-
fication of all available targets on the surface of pediatric cancers.
We propose that this approach will be especially valuable in solid
tumors, as a paucity of well-described targets remains a chal-
lenge to the field. The data we present here should allow for the
rapid assessment of these target antigens for their suitability as
candidates for immunotherapy.
MATERIALS AND METHODS
EXPRESSION DATABASE FOR PEDIATRIC TUMORS
The Pediatric Tumor Affymetrix Database is freely accessible and
can be found on-line at the NCI Pediatric Oncology Branch
Oncogenomics Section web-site2. The gene chip used was U133
P2 (Affymetrix, Santa Clara, CA, USA).
CONSTRUCTION OF AN ALGORITHM TO IDENTIFY CANDIDATE
MEMBRANE PROTEINS FOLLOWING DISEASE-SPECIFIC ANALYSIS OF
GENE EXPRESSION
The design of this program was broken down into stages. First,
annotation data from several public databases were collated and
used to identify cell surface proteins. This included Gene Ontol-
ogy3, Affymetrix chip data references, the Human Protein Refer-
ence Database4, and the primary literature. Second, a database was
constructed using this data, along with our gene expression data,
to store the data in a usable format for analysis in MySQL, using a
set of Python scripts to automate core database functions. Using
this database, an auxiliary table was built, combining gene expres-
sion levels over tissue sample categories, corresponding specifically
to samples from indicated pediatric cancers, using a two-sampled
t -test (implemented using the SciPy Python package for scien-
tific and statistical functions) with all samples in each category
tested against a series of normal tissue samples (expression pro-
files of lung, liver, kidney, heart, adrenal, cerebrum, cerebellum,
uterus, testes, stomach, spleen, bladder, skeletal muscle, prostate,
and ovary, previously described in; Whiteford et al., 2007) in order
to generate a T -statistic and p value, scoring each gene’s expression
level in each cancer type vs. normal expression levels. Genes in this
auxiliary table were then sorted in order of descending differential
expression.
RESULTS
TUMORS ANALYZED
We restricted our current analysis to the 12 pediatric tumor
types that had more than five samples available in the Pediatric
Tumor Affymetrix Database: Pre-B Acute Lymphocytic Leukemia
2http://home.ccr.cancer.gov/oncology/oncogenomics/
3http://www.geneontology.org
4http://www.hprd.org/
(Pre_B_ALL), Embryonal Rhabdomyosarcoma (ERMS), Alve-
olar Rhabdomyosarcoma (ARMS), Soft-Tissue Sarcoma (STS)
that is not classified as Rhabdomyosarcoma (Non-RMS_STS or
simply STS), Desmoplastic Small Round Cell Tumor (DSRCT),
Ewing’s Sarcoma (EWS), Alveolar Soft Part Sarcoma (ASPS),
Glioblastoma (GBM), Osteosarcoma (OS), Neuroblastoma-
MYCN-amplified (NBL_MA, MYCNA-NBL), Neuroblastoma
non-MYCN-amplified (NBL), and Hepatoblastoma (HBL). Some
well-known tumors, like Wilm’s tumor, could not yet be included;
nevertheless, these 12 types represent the majority of all pediatric
solid tumors, and also includes the most common hematologic
malignancy of children.
CANDIDATE ANTIGENS
We present here Pre_B_ALL as an example to demonstrate how
data mining searches were organized. A standard t -test was used
to compare the average gene expression signal from tumor vs. the
set of normal tissues analyzed in the database. The normal tissue
data was used as an aggregate average expression score per each
query. The algorithm was also set to report out a p value, while
filtering for surface membrane expression to define the targets of
interest. We initially calculated t-test values> 10, and ordered the
output to select for the highest T values. This process was repeated
in a similar manner for each disease category. Table 1 shows the
number of hits for each disease type in the database returned when
this arbitrary T threshold of>10 was selected. A wide range of hits
was returned, with some diseases like ARMS having 62 hits score
above 10, while DSRCT had 0. This does not mean DSRCT has no
significant hits, as a T -statistic of 10 is a very high-value. Rather it
illustrates that on a global level each malignancy has developed its
own phenotypic“distance”from the normal cell surface landscape.
A major challenge for our approach is that annotation of
membrane-associated protein expression has not (or perhaps cur-
rently cannot) been validated for accuracy. On-line programs such
Table 1 |Tumor-associated membrane proteins identified with aT
value greater than 10.
Disease Sample size, n= Hits
Pre-B ALL 9 120
ARMS 12 62
ASPS 7 52
Glioblastoma 7 52
NBL-MYCN-amplified 24 44
Non-RMS-STS 6 38
Osteosarcoma 17 31
Hepatoblastoma 7 24
Ewing’s sarcoma 19 22
ERMS 9 16
Neuroblastoma (NBL) 15 4
DSRCT 8 0
The table lists the 12 disease categories analyzed and the number of individual
gene expression profiles for each disease type currently featured in the Oncoge-
nomics database. “Hits” refers to the number of tumor-associated membrane
antigens reported whose T value is>10 in comparison to normal.
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as the highly sophisticated TMHMM package5 can predict trans-
membrane structure, but cannot assign sub-cellular localization.
The most extensive and accurate protein database groups (for
example the Human Protein Reference Database/Pandey Lab6) are
hand-annotating proteins and tracing them to the original litera-
ture in order to define sub-cellular localization. Therefore, we also
had to utilize this approach and individually examine each mem-
brane protein hit yielded by our algorithm by searching the avail-
able primary literature, primarily using Gene hosted by NCBI7,
to determine if the “membrane” tag associated with a transcript’s
annotation truly denotes the extracellular plasma membrane. If an
antigen is not expressed at the surface, that antigen will not be use-
ful for immune targeting as we have described. We thus excluded
proteins restricted to the mitochondria, nuclear membrane, Golgi,
endoplasmic reticulum, sorting vesicles, and other intracellular
membrane-bound bodies. Membrane proteins expressed both on
the surface and another sub-cellular compartment were included.
Table 2 lists the top 25 extracellular membrane proteins for each
disease type after individual annotation/inspection.
To compare global differences in the immune landscape for the
25 antigens most different from normal for each tumor type, we
plotted the T value range of those 25 hits for each tumor type,
Figure 1. When comparing the expression of a particular tran-
script in a tumor type versus normal tissue, we used a T -statistic
and report the associated p value for that particular transcript
(both with respect to difference from normal tissue). In looking at
the top 25 hits for each tumor type, the lowest set of T values (that
is membrane proteins that were least distinct from normal), were
DSRCT and NBL. T values ranged from 9.3 to 6.9 for DSRCT and
from 12.6 to 5.8 for NBL. The highest T values (tissues scoring the
most different from normal) were seen for ASPS, Pre-B ALL, STS,
and ARMS, which scored from 25.5 to 12.5, 19.8 to 11.0, 15.0 to
9.8, and 27.7 to 10.0, respectively. When p values were evaluated an
essentially inverse pattern was seen; that is, high scoring T values
had smaller (more significant) p values (not shown). These values
demonstrate very good separation from normal and represent a
set of targets that are important to further evaluate in each of these
tumor types. As to the true immunogenicity of these tumor types,
further studies are required to determine whether these differences
can be accounted for by different strategies of immune escape or
immune editing (Schreiber et al., 2011).
To better understand the antigens we have identified, we
ordered the transcripts according to functional groups (Table 3).
The first group consists of known CD antigens or immune marker
proteins. The possession of a CD designation ensures that an anti-
body has been created to that transcript. The only known CD
antigen we did not list in this section was CD222 (glucagon-like
peptide 1 R), which was placed in the growth factor receptor cat-
egory. In the CD antigen group, 12 out of 47 (appx. 25%) are
expressed in pre-B ALL. This is representative of the tissue of ori-
gin, as CD antigens are often of immune cell origin. Nevertheless,
many CD antigens are also expressed on other pediatric tumors.
5http://www.cbs.dtu.dk/services/TMHMM/
6http://pandeylab.igm.jhmi.edu
7http://www.ncbi.nlm.nih.gov/gene
Table 2 |Top 25 pediatric cancer transcripts arranged by category.
CD antigens/immunology markers
CD19, B cell marker
CD22, B cell marker
CD25, IL2RA
CD28
CD30, TNFRSF8
CD43, sialophorin
CD49D, ITGA4 (VLA-4)
CD53 (a tetraspanin)
CD72, B cell marker
CD73, NT5E
CD79A, B cell marker
CD79B, B cell marker
CD85k, LILRB4, ILT3, leukocyte Ig-like R, subfamily B, member 4
CD107a
CD112, PVRL2 poliovirus R-related 2
CD115, CSF1R, colony-stimulating factor 1 receptor
CD146, MCAM, MUC18
CD155, PVR, polio-virus receptor
CD185, CXCR5
CD204, MSR1, macrophage scavenger receptor 1
CD271, NGFR
CD276, B7-H3
CD279, PDCD1 (PD1)
CD280, MRC2, mannose R, C-type 2
CD281, TLR1, toll-like receptor 1
CD301 (CLEC10A)
CD353, SLAMF8
CD362, SDC2, syndecan 2
CKLF, chemokine-like factor
CLEC2D, C-type lectin domain family 2, member D (NK cells)
FLT3LG
GP1BB glycoprotein Ib, β polypeptide, CD42c
HLA-G
ICAM5, telencephalin
IGHA1/IgA1
IL1RAP, IL-1R accessory protein
IL17RE, Interleukin-17 receptor E
IL27RA, on EWS
MILR1, mast cell Ig-like receptor 1
MR1, MHC class 1-related
PTCRA, pre-TCR α
PODXL2, endoglycan, podocalyxin-like 2
PTPRCAP, CD45-AP
ULBP2, UL16 binding protein 2, NKG2D ligand 2, on OS
XG, Xg blood group
Cell adhesion, cell junction
AJAP1 Adherens Junction Associated (SHREW-1, binds CD147)
ASGR1, R2 (asialoglycoprotein receptor)
MILR1, mast cell Ig-like 1, Allergin-1
CADM1/IGSF4A, cell adhesion molecule 1
CADM4/IGSF4C
CDH15, cadherin 15, type 1, myotubule
(Continued)
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Table 2 | Continued
CDH23, cadherin-related 23
CDHR5, MUCDHL
CELSR3, cadherin, EGF LAG seven-pass G-type receptor 3
CSPG4, chondroitin sulfate proteoglycan 4 (HMW-MAA,
melanoma-associated)
FAT4, FAT tumor suppressor homolog 4, protocadherin CDHF14
GJA3, gap junction protein α 3 (connexin family)
GJB2, gap junction protein β 2
GPC2, glypican-2
IGSF9, Ig superfamily, member 9
LRFN4, leucine-rich repeat (LRR), and fibronectin type III domain
containing 4
LRRN6A/LINGO1, LRR, and Ig domain containing 1
LRRC15, LRR containing 15
LRRC8E, LRR containing 8E
LRIG1, LRR, and Ig-like domains 1
LGR4, LRR containing G-protein-coupled receptor 4 (R-spondin receptor)
LYPD1, LY6/PLAUR domain containing 1
MARVELD2, MARVEL domain containing 2
MEGF10, multiple EGF-like domains 10, scavenger/phagocytic R
MPZL1, myelin protein zero-like 1
MTDH, metadherin
PANX3, pannexin 3
PCDHB10, protocadherin β 10
PCDHB12, protocadherin β 12
PCDHB13, protocadherin β 13
PCDHB18, protocadherin β 18 pseudogene
PCDHGA3, protocadherin γ subfam. A, 3
PERP, TP53 apoptosis effector
SGCB, sarcoglycan, β
VEZT, vezatin, adherens junctions transmembrane protein
Enzymatic function
DAGLB, diacylgycerol lipase β
SYT11, synaptogamin XI
WFDC10A, WAP four-disulfide core domain 10A, peptidase inhibitor,
extracellular
Growth factor R/development R
ACVR2A, Activin R2A
ACVR2B, Activin R2B
EPHB2, ephrin receptor B2 (RTK)
EPHB3, ephrin receptor B3
EPHB4, ephrin receptor B4
EFNB1, ephrin-B1
EPOR, erythropoietin receptor
FGFR2, fibroblast growth factor receptor 2
FGFR4
GALR2, galanin receptor 2 (GPCR)
GLG1, Golgi glycoprotein 1, Cfr-1, cysteine rich FGFR, ESL-1, E-selectin
ligand-1
GLP1R, glucagon-like peptide 1 R
HBEGF, heparin-binding EGF-like growth factor (cleaved at membrane)
IGF2R insulin-like growth factor-2 receptor
MET, met proto-oncogene, HGFR, hepatocyte growth factor receptor
(Continued)
UNC5C, unc-5 homolog C, a netrin R
VASN, vasorin, TGF-β R on vascular smooth muscle cells
DLL3, delta-like 3, a notch ligand
FZD10/CD350, frizzled homolog 10 (GPCR, Wnt pathway)
KREMEN2, kringle containing transmembrane protein 2 (DKK1 receptor)
TMEM198, MGC99813, required for Wnt signal transduction
NRG1, neuregulin 1
TMEFF1, transmembrane protein w/EGF-like, and two follistatin-like
domains 1
Neurotransmitter receptor
ADRA2C, adrenergic A2C
CHRNA1, cholinergic R, nicotinic, α 1 (muscle)
CHRNB4, cholinergic R, nicotinic, β 4
CHRNA3, cholinergic R, nicotinic, α 3
CHRNG, cholinergic R, nicotinic, γ
DRD4, dopamine R D4, G-protein linked
GABRB3, GABA receptor, β3
GRIN3A, glutamate R, ionotropic, N -methyl-d-aspartate 3A
GRIN2C glutamate R, ionotropic, N -methyl d-aspartate 2C
GRIK4 glutamate R, ionotropic, kainate 4
HTR7 5-hydroxytryptamine (serotonin) R 7
SLC6A2, solute carrier family 6 (neurotransmitter, noradrenalin), member 2
SLC6A11, SLC6 (neurotransmitter transporter, GABA), member 11
SLC6A15, SLC (neutral amino acid transporter), member 15
SLC29A4, SLC29 (nucleoside transporters), member 4 (reuptake of
monoamines into presynaptic neurons)
Ion channels, ion channel regulation
APT8B2 (ATPase, cation transport, phospholipid translocation)
NKAIN4 (C20orf58), Na+/K+ transporting ATPase interacting 4.
CACNA1A,Ca2+ channel, voltage-dependent, P/Q type, α 1A subunit
CACNA1B, Ca2+ channel, voltage-dependent, L type, α 1B subunit
CACNA1I, Ca2+ channel, voltage-dependent, α 1I subunit
CACNG8, Ca2+ channel, voltage-dependent, γ subunit 8
CACNG4, Ca2+ channel, voltage-dependent, γ subunit 4
CLCN7, chloride channel 7
NKAIN1, Na+/K+ transporting ATPase interacting 1, FMA77C
NKAIN4, Na+/K+ transporting ATPase interacting 4, C20orf58
KCNEA4, K+ voltage-gated channel, Isk-related family, member 4
KCNG2, K+ voltage-gated channel, subfamily G, member 2
KCNN3, K+ intermediate/small conductance Ca2+-activated channel,
subfamily N, member 3
KCNQ2, K+ voltage-gated channel, KQT-like subfamily, member 2
KCNU1, K+ channel, subfamily U, member 1
P2RX3, purigenic receptor P2X, ligand-gated ion channel, 3
PKD1L2, polycystic kidney disease 1-like 2
PKD2L1, polycystic kidney disease 2-like 1
SLC9A1, SLC9 (Na+/H+ exchanger), member 1
SLC30A5, SLC30 (zinc transporter), member 5
SLC39A7, SLC39 (zinc transporter), member 7
SLC39A8, SLC39 (zinc transporter), member 8
TRPM4, transient receptor, potential cation channel, subfamily M, member
4
TRPV4, transient receptor, potential cation channel, subfamily V, member 4
(Continued)
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Table 2 | Continued
TMEM16J/ANO9, anoctamin 9, Ca2+-activated Cl- channel
TMEM142B, ORAI2, ORAI Ca2+ release-activated Ca2+modulator 2
SLC, solute carrier family members
SLC6A15, SLC6 (neutral amino acid transporter), member 15
SLC5A8, SLC5 (iodide transporter), member 8
SLC7A1, SLC7 (cationic amino acid transporter, y+ system), member 1
SLC7A6, SLC7 (amino acid transporter light chain, y+L system), member
6
SLC10A3, SLC10 (sodium/bile cotransporter family), member 3
SLC10A4, SLC10 (sodium/bile acid cotransporter family), member 4
SLC13A5, SLC13 (sodium-dependent citrate transporter), member 5
SLC16A8, SLC16, member 8 (monocarboxylic acid transporter 3)
SLC19A1, FOLT, SLC19 (folate transporter), member 1
SLC35E2, SLC35, member E2
SLC38A6, SLC38, member 6
SLC38A9, SLC38, member 9 (putative sodium-coupled neutral amino acid
transporter 9)
SLC43A3, EEG1 (embryonic epithelial gene-1), SLC43, member 3
G-protein, G-protein coupled, or associated receptor
ADORA2B, Adenosine R
BAI1 (brain angiogenesis inhibitor 1)
EDG6, S1PR4, sphingosine-1-phosphate R4
GPR1, G-coupled protein receptor 1
GPR26
GPR34
GPR44, PTGDR2 prostaglandin D2 receptor 2
GPR56
GPR68 (OGR-1, ovarian cancer G-protein-coupled receptor 1)
GPR175, TPRA1 transmembrane protein, adipocyte associated 1
LGR4, LRR containing G-protein-coupled receptor 4
MMD, monocyte macrophage differentiation-associated (has 7
transmembrane domains, not proven as a GPCR)
NTSR2, neurotensin receptor 2
OPN3, opsin 3
OR2L2, olfactory R, family 2, subfamily L, member 2
OSTM1, osteopetrosis associated transmembrane protein 1
P2RY8, purinogenic R P2Y, G-coupled, 8
P2RY11, purinogenic R P2Y, G-coupled, 11
PTGE3, prostaglandin E R 3 (subtype EP3)
SSTR5, somatostatin R 5
TBXA2R, thromboxane A2 receptor
Migration/metastasis/motility
ADAM22
CST11, cystatin 11 (epididymal specific)
MMP14, matrix metallopeptidase 14
LPPR1, RP11-35N6.1, lipid phosphate phosphatase-related protein type 1
LPPR3, PRG2 (plasticity related gene 2), LPPR type 3
LPPR5, PAP2D, PRG5, LPPR type 5
SEMA6B, semaphorin 6B
Tetraspanin
ALS2CR4 (amyotrophic lateral sclerosis 2 [juvenile])
LEPROTL1, leptin R overlapping transcript-like 1
(Continued)
MS4A4A, membrane-spanning, 4-domains, subfamily A, member 4A,
CD20L1
MS4A6A, membrane-spanning 4-domains, subfamily A, member 6A,
CD20L3
ROM1, retinal outer segment membrane protein 1
TM4SF5, transmembrane 4 L six family member 5
VANGL1, vang-like 1 (van gogh, Drosophila)
VANGL2, vang-like 2
Uncharacterized
C18orf1 (contains a LDLRA domain)
GSGL1, germ cell specific gene 1-like
ITM2A, integral membrane protein 2A
KIAA1715, LNP
LDLRAD3 (provisional), LDL receptor class A domain containing 3
ODZ3,odz Oz/ten-m homolog 3
SLC7A5P1 (LAT1-3TM) SLC7 (aminoacid transporter light chain, L system),
member 5, psuedogene-1
STEAP1, six transmembrane epithelial antigen of the prostate 1
The pediatric top 25.The membrane-bound proteins with the highestT value with
respect to normal tissue expression are listed by disease type. ALL, Pre-B, Acute
Lymphocytic Leukemia; ASPS, Alveolar Soft Part Sarcoma; DSRCT, Desmoplastic
Small Round Cell Tumor; ERMS, Embryonal Rhabdomyosarcoma; ARMS, Alve-
olar Rhabdomyosarcoma; Non-RMS_STS or simply STS, Soft-Tissue Sarcoma
that is not classified as Rhabdomyosarcoma; EWS, Ewing’s Sarcoma; GBM,
Glioblastoma; OS, Osteosarcoma; NBL_MA, MYCNA-NBL, Neuroblastoma-
MYCN-amplified; NBL, Neuroblastoma non-MYCN-amplified; HBL, Hepatoblas-
toma.This list was individually annotated to include only those transcripts whose
proteins could be targeted from their extracellular aspect.
FIGURE 1 |T -Statistic overview of the top 25 tumor-specific
transcripts. For each disease category (listed on the x -axis), the range of
T -statistic values for the 25 membrane proteins most different from normal
tissue, along with their average and quartiles, is represented as a box and
whisker plot.
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Antigens in the “Cell Adhesion, Cell Junction” group include
well-known adhesion family receptor members, like cadherins,
cell-to-cell junction associated proteins, and other scavenger or
immunoglobulin-related proteins. One would expect that the pro-
teins in this family also would readily have antibodies created to
them, and are likely to receive CD designations in the future. This is
also likely to be true for the“Growth Factor Receptor/Development
Receptor” grouping. These hits also provide ready targets such as
the FGFR2, FGFR4, known oncogenes like MET, and the activin
and ephrin receptors, that are likely to be linked to the oncogenic
activation of the cancer tissues in which they are expressed. The
final groups of cell surface proteins that are likely to be targetable
are the“Migration/Metastasis/Motility”and the“Enzymatic Func-
tion” group. In general these proteins exhibit their activity outside
of the cell and mediate interaction of the cell with its surrounding
matrix.
Comprising about half the proteins on the list are membrane-
expressed proteins to which it cannot be assumed an antibody or
CAR exists or that could be readily generated. These groups are the
Neurotransmitter Receptors, Ion Channels, Solute Carrier Family,
Tetraspanin, and G-protein groups. Although exceptions certainly
exist, these membrane proteins interact with small molecules or
ions and transport them across the cell membrane, or they co-
ordinate other proteins within the membrane. In general they do
not evidence a large extracellular component.
Another way to ascribe relative value to the “hits” we have iden-
tified is to determine how broadly they are expressed across the
different pediatric cancer types. Figure 2 demonstrates that 12
proteins are expressed in at least three distinct disease categories,
and that another 12 transcripts are expressed in more than three
disease types. From this view, the highest value targets are MCAM
and GPC2, which are expressed in the Top 25 for eight differ-
ent cancers. Similarly, small molecule transporters like SLC19A1
and neurotransmitter receptors like purogenic G-protein coupled
(P2RY11) are prevalent across histologies. Whether the limited
size of their extracellular domains will affect the ability to tar-
get these antigens with antibody derivatives or CARs is unknown,
but their prevalence across disease types makes this an interesting
question.
TARGET-SPECIFIC OBSERVATIONS
The ability of our algorithm to identify high-value targets is
demonstrated by our results for Pre-B ALL, where a number of cell
surface molecules currently being targeted in the clinic were iden-
tified as hits, Table 2. One of the most important immunother-
apeutic trials to date features CAR-modified T-cells specific for
CD19, which is the top hit for B_ALL (Kochenderfer et al., 2010;
Porter et al., 2011). Another Top 25 hit, CD22, is the target of an
antibody-toxin conjugate experimental protocol that continues to
show promise for children with ALL (Mussai et al., 2010). Another
target, CD79 is also the subject of interest in therapy for B cell
malignancy, as antibody-drug conjugates are being developed and
tested (Polson et al., 2007). While our bioinformatic approach is
validated by these results with ALL, the value of our approach is in
the identification of antigens of interest for pediatric solid tumors
for which substantial numbers of candidate antigens have not been
previously identified.
The two most broadly expressed targets we identified for pedi-
atric solid tumors are melanoma cell adhesion molecule (MCAM,
CD146, MUC18), and glypican-2 (GPC2). MCAM and GPC2
are expressed in eight of the 12 tumor types analyzed, Figure 2.
The other most commonly expressed adhesion molecule, metad-
herin (MTDH), is expressed in four of 12 tumor types. MCAM is
involved in the pathogenesis of melanoma, breast carcinoma, and
other cancers (Wu et al., 2011; Zeng et al., 2012). Both antibody-
based and vaccine approaches targeting MCAM/MUC18 have
been proposed (Melnikova and Bar-Eli, 2006; Leslie et al., 2007).
GPC2 (also know as cerebroglycan) is normally expressed in the
developing brain (Stipp et al., 1994). Molecules in the same fam-
ily, Glypican-3 and Glypican-5, have been described in melanoma,
neuroblastoma, and rhabdomyosarcoma (Saikali and Sinnett,
2000; Nakatsura et al., 2004a,b; Williamson et al., 2007). Our report
here of the specific expression of Glypican-2 on pediatric tumors
should now focus attention on this glypican as well. Metadherin
(MTDH) is expressed on hepatocellular carcinoma, may play a
role in epithelial-to-mesenchymal transition (Zhu et al., 2011),
and plays a role in the metastatic spread of breast cancer to the
lung (Brown and Ruoslahti, 2004). These three adhesion receptors
are therefore top candidates to explore further as targets in pedi-
atric tumors given their overexpression and the ability to create
antibodies against cell surface adhesion receptors.
The largest family of cell surface proteins is the G-proteins
(GPCR, approximately 800 members), followed by the solute car-
rier family (SLC, approximately 380 members; Almen et al., 2009;
Hoglund et al., 2011). One of our top hits, SLC19A1 (expressed in
ALL, HBL, MYCNA-NBL, GBM, ERMS, and ARMS), is a folate
transporter. Unlike the GPI-linked α folate receptor (FOLR1),
which is currently the target of antibody-based trials, SLC19A1
(FOLT) is a multi-pass membrane protein that looks very much
like an ion channel (Konner et al., 2010). Each of the SLC proteins
are regulated in expression, responsive to cellular stress or nutri-
tional requirement, and could serve as suitable immune targets,
but little is known about targeting them. The better known GPCR,
ion channels, and neurotransmitter receptors we have described
have in some cases had antibodies produced against them. In gen-
eral, producing antibodies, and therefore scFv and CARs, against
multi-membrane pass proteins with limited extracellular sequence
is more difficult than for proteins with large extracellular domains.
The solid pediatric malignancies we analyzed also preferen-
tially overexpress a number of receptors associated with the activin
and ephrin receptor systems. Hits in the activin family include
ACVR2A (ERMS, ARMS), ACVR2B (HBL); and in the ephrin
family, EPHB2 (DRCT, HBL), EPHB3 (DRCT), EPHB4 (ERMS,
DRCT), and EFNB1 (EWS). Activins are growth factors in the
TGF-β family that bind dual chain receptors composed of ligand-
binding and signaling subunits. The ACVR2 chains have the ability
to signal as constitutive kinases and are thought to regulate mus-
cle growth through binding of myostatin (Lee et al., 2005). The
ACVR2A/2B expression patterns and their biological activity make
them very high-value hits for pediatric oncology. Ephrins function
in neuronal development and are divided in to A and B types, as
are the receptors that bind to them. The ligand, ephrin-B1, is a
transmembrane protein and the receptors we list as Top 25 hits,
all in the receptor tyrosine kinase family, are also of the B type.
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Affy ID Gene symbol T value P value Gene name
ALL (PRE-B)
1 206398_s_at CD19 19.85 1.56E−15 CD19 molecule
2 205049_s_at CD79A 17.90 1.33E−14 CD79a, immunoglobulin-associated alpha
3 205885_s_at CD49D 16.64 6.01E−14 Integrin, alpha 4 (VLA-4)
4 205297_s_at CD79B 16.18 1.06E−13 CD79b, immunoglobulin-associated beta
5 1568964_x_at CD43 15.80 1.71E−13 Sialophorin (leukosialin)
6 222935_x_at SLC39A8 14.78 6.59E−13 Solute carrier family 39 (zinc transporter)
7 209776_s_at SLC19A1 13.84 2.47E−12 Solute carrier family 19 (folate transporter)
8 204960_at CD45-AP 13.59 3.50E−12 PTPRCAP, CD45-associated protein
9 229686_at P2RY8 13.57 3.61E−12 Purinergic R P2Y, G-protein coupled, 8 (fused w/CRLF2 in
pre-B ALL (Mullighan’09)
10 214546_s_a P2RY11 13.26 5.73E−12 Purinergic R P2Y, G-protein coupled, 11
11 236186_x_at IL17RE 13.22 6.03E−12 Interleukin 17 receptor E
12 210176_at CD281 12.70 1.32E−11 Toll-like receptor 1
13 206437_at SIPR4 12.64 1.46E−11 Sphingosine-1-phosphate R 4, EDG6
14 215925_s_at CD72 12.58 1.60E−11 CD72 molecule
15 212250_at MTDH 12.47 1.89E−11 Metadherin
16 211042_x_at CD146/MCAM 12.38 2.18E−11 Melanoma cell adhesion molecule (MUC18)
17 220132_s_at CLEC2D 12.03 3.77E−11 C-type lectin domain family 2, member D
18 217513_at MILR1 11.66 6.94E−11 Mast cell immunoglobulin-like receptor 1
19 208590_x_at GJA3 11.38 1.09E−10 Gap junction protein, alpha 3, 46kDa
20 217422_s_at CD22 11.33 1.18E−10 CD22 molecule
21 209574_s_at C18orf1 11.29 1.26E−10 Chromosome 18 open reading frame 1
22 203578_s_at SLC7A6 11.09 1.78E−10 SLC7 (cationic a. a. transporter), member 6
23 239422_at GPC2 11.09 1.79E−10 Glypican 2 (cerebroglycan)
24 208299_at CACNA1I 11.07 1.85E−10 Ca channel, voltage-dep., alpha 1I subunit
25 203416_at CD53 11.05 1.91E−10 CD53 molecule
ASPS
1 209963_s_at EPOR 25.54 1.90E−20 Erythropoietin receptor
2 235197_s_at OSTM1 24.96 3.45E−20 Osteopetrosis assoc. transmembr. protein 1
3 227393_at ANO9 22.55 4.75E−19 Anoctamin 9 (TMEM16J)
4 244444_at PKD1L2 18.60 6.34E−17 Polycystic kidney disease 1-like 2
5 202827_s_at MMP14 18.42 8.12E−17 Matrix metallopeptidase 14
6 222379_at KCNE4 15.65 4.62E−15 K voltage-gated channel, member 4
7 234985_at LDLRAD3 15.45 6.23E−15 LDL receptor class A domain containing 3
8 206899_at NTSR2 15.25 8.68E−15 Neurotensin receptor 2
9 219607_s_at MS4A4A/CD20L1 15.07 1.16E−14 Membrane-spanning 4-domains, A4
10 230550_at MS4A6A/CD20L3 14.78 1.83E−14 Membrane-spanning 4-domains, A6
11 38069_at CLCN7 14.49 2.96E−14 Chloride channel 7
12 214830_at SLC38A6 14.21 4.77E−14 Solute carrier family 38, member 6
13 206582_s_at GPR56 14.14 5.32E−14 G protein-coupled receptor 56
14 201393_s_at IGF2R/CD222 13.93 7.66E−14 Insulin-like growth factor 2 receptor
15 206545_at CD28 13.49 1.63E−13 CD28 molecule
16 208552_at GRIK4 13.48 1.65E−13 Glutamate receptor, ionotropic, kainate 4
17 219764_at FZD10/CD350 13.34 2.12E−13 FZD10/frizzled homolog 10
18 223620_at GPR34 13.03 3.69E−13 G protein-coupled receptor 34
19 210514_x_at HLA-G 13.00 3.87E−13 HLA-G histocompatibility antigen, class I, G
20 214770_at MSR1/CD204 12.86 5.05E−13 Macrophage scavenger receptor 1
21 206980_s_at FLT3LG 12.79 5.70E−13 Fms-related tyrosine kinase 3 ligand
22 203104_at CSF1R/CD115 12.76 6.06E−13 Colony stimulating factor 1 receptor
23 207565_s_at MR1 12.58 8.32E−13 MHC, class I-related
24 213728_at CD107a 12.50 9.76E−13 LAMP1
25 210692_s_at SLC43A3 12.48 1.01E−12 Solute carrier family 43, member 3 (EEG)
(Continued)
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DRCT
1 212662_at CD155 9.34 6.28E−09 Poliovirus receptor
2 211879_x_at PCDHGA3 9.13 9.24E−09 Protocadherin gamma subfamily A, 3
3 206083_at BAI1 8.81 1.71E−08 Brain-specific angiogenesis inhibitor 1
4 219692_at KREMEN2 7.80 1.24E−07 Kringle containing transmembrane protein 2
5 214546_s_at P2RY11 7.71 1.49E−07 Purinergic R P2Y, G-protein coupled, 11
6 215169_at SLC35E2 7.66 1.63E−07 Solute carrier family 35, member E2
7 227281_at SLC29A4 7.62 1.78E−07 SLC29 (nucleoside transporters), member 4
8 210651_s_at EPHB2 7.51 2.22E−07 EPH receptor B2
9 204600_at EPHB3 7.43 2.64E−07 EPH receptor B3
10 208215_x_at DRD4 7.39 2.85E−07 Dopamine receptor D4
11 207634_at CD279/PD1 7.38 2.91E−07 Programmed cell death 1
12 220798_x_at LPPR3/PRG2 7.32 3.33E−07 Lipid phosphate phosphatase-related pr. 3
13 239422_at GPC2 7.18 4.49E−07 Glypican 2 (cerebroglycan)
14 230668_at NKAIN4 7.17 4.56E−07 Na++/K++ transporting ATPase interacting 4
15 206906_at ICAM5 6.97 6.92E−07 Intercellular adhesion molecule 5
16 203149_at CD112 6.82 9.71E−07 PVRL2, poliovirus receptor-related 2
17 204736_s_at CSPG4 6.77 1.07E−06 Chondroitin sulfate proteoglycan 4
18 222293_at CADM4/IGSF4C 6.69 1.29E−06 IGSF4C, Ig superfamily member 4C
19 206460_at AJAP1 6.64 1.43E−06 Adherens junction assoc. prot. 1 (SHREW-1)
20 232415_at PCDHB13 6.60 1.54E−06 Protocadherin beta 13
21 206341_at CD25 6.57 1.66E−06 Interleukin 2 receptor, alpha
22 236186_x_at IL17RE 6.45 2.16E−06 Interleukin 17 receptor E
23 208590_x_at GJA3 6.40 2.42E−06 Gap junction protein, alpha 3, 46kDa
24 214605_x_at GPR1 6.31 2.96E−06 G protein-coupled receptor 1
25 216680_s_at EPHB4 6.29 3.10E−06 EPH receptor B4
EWS
1 1554062_at XG 11.76 3.69E−13 Xg blood group
2 212250_at MTDH 10.10 1.76E−11 Metadherin
3 218989_x_at SLC30A5 10.08 1.86E−11 SLC30 (zinc transporter), member 5
4 223675_s_at VEZT 10.05 2.01E−11 Vezatin
5 205542_at STEAP1 9.96 2.49E−11 6 transmembr. epithelial ag of the prostate 1
6 219427_at FAT4 9.94 2.62E−11 FAT tumor suppressor homolog 4
7 220798_x_at LPPR3/PRG2 9.78 3.90E−11 Lipid phosphate phosphatase-related prot. 3
8 239422_at GPC2 9.51 7.60E−11 Glypican 2 (cerebroglycan)
9 235241_at SLC38A9 9.51 7.64E−11 Solute carrier family 38, member 9
10 227933_at LRRN6A/LINGO1 9.41 9.91E−11 Leucine rich repeat neuronal 6A
11 211042_x_at CD146/MCAM 9.27 1.38E−10 Melanoma cell adhesion molecule (MUC18)
12 224392_s_at OPN3 9.15 1.89E−10 Opsin 3 (encephalopsin, panopsin)
13 208299_at CACNA1I 9.15 1.90E−10 Voltage-dependent, alpha 1I subunit
14 219360_s_at TRPM4 9.11 2.11E−10 Transient R potential cation channel, M4
15 208550_x_at KCNG2 8.71 5.86E−10 Voltage-gated channel, subfamily G2
16 212909_at LYPD1 8.50 1.03E−09 LY6/PLAUR domain containing 1
17 205227_at IL1RAP 8.50 1.04E−09 Interleukin 1 receptor accessory protein
18 214730_s_at GLG1 8.44 1.22E−09 Golgi apparatus protein 1 (SEMA6C)
19 202747_s_at ITM2A 8.41 1.30E−09 Integral membrane protein 2A
20 209768_s_at CD42c 8.41 1.32E−09 GP1BB, glycoprotein Ib (platelet), beta
21 222062_at IL27RA 8.34 1.56E−09 Interleukin 27 receptor, alpha
22 225717_at KIAA1715 8.29 1.78E−09 KIAA1715 (Lnp, Lunapark)
23 202711_at EFNB1 8.28 1.86E−09 Ephrin-B1
24 214830_at SLC38A6 8.25 2.01E−09 Solute carrier family 38, member 6
25 236186_x_at IL17RE 7.31 2.58E−08 Interleukin 17 receptor E
(Continued)
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GBM
1 208590_x_at GJA3 11.85 1.69E−10 Gap junction protein, alpha 3, 46kDa
2 222935_x_at SLC39A8 11.16 4.88E−10 SLC39 (zinc transporter), member 8
3 217573_at GRIN2C 11.02 6.04E−10 Glutamate R, ionotropic, NMDA 2C
4 212250_at MTDH 10.77 8.95E−10 Metadherin
5 236186_x_at IL17RE 10.71 9.80E−10 Interleukin 17 receptor E
6 211226_at GALR2 10.19 2.31E−09 Galanin receptor 2
7 205806_at ROM1 9.72 5.12E−09 Retinal outer segment membrane protein 1
8 205891_at ADORA2B 9.71 5.16E−09 Adenosine A2b receptor
9 232432_s_at SLC30A5 9.64 5.83E−09 SLC30 (zinc transporter), member 5
10 208299_at CACNA1I 9.50 7.47E−09 Ca channel, voltage-dependent, alpha 1I
11 222596_s_at LGR4 9.47 7.87E−09 Leucine-rich repeat-containing GPCR4
12 208550_x_at KCNG2 9.09 1.55E−08 K voltage-gated channel, subfamily G2
13 1553995_a_at CD73 9.08 1.56E−08 5′-Nucleotidase, ecto
14 207048_at SLC6A11 8.99 1.84E−08 SLC6 (GABA transporter), member 11
15 205120_s_at SGCB 8.79 2.66E−08 Sarcoglycan, beta
16 235197_s_at OSTM1 8.77 2.74E−08 Osteopetrosis assoc. transmembrane prot. 1
17 1556990_at PERP 8.70 3.14E−08 PERP, TP53 apoptosis effector
18 223451_s_at CKLF 8.68 3.25E−08 Chemokine-like factor
19 211042_x_at CD146/MCAM 8.65 3.40E−08 Melanoma cell adhesion molecule (MUC18)
20 240140_s_at LRIG1 8.61 3.69E−08 Leucine-rich repeats and Ig-like domains 1
21 214546_s_at P2RY11 8.55 4.11E−08 Purinergic R P2Y, G-protein coupled, 11
22 208229_at FGFR2 8.28 6.85E−08 Fibroblast growth factor receptor 2
23 202667_s_at SLC39A7 8.26 7.09E−08 SLC39 (zinc transporter), member 7
24 209776_s_at SLC19A1 8.26 7.13E−08 SLC19 (folate transporter), member 1
25 216464_x_at PTGDR2 8.15 8.72E−08 Prostaglandin D2 receptor 2/CD294
HBL
1 206242_at TM4SF5 15.37 1.54E−12 Transmembrane 4 L six family member 5
2 212662_at CD155 14.66 3.68E−12 Poliovirus receptor
3 235955_at MARVELD2 12.90 3.75E−11 MARVEL domain containing 2
4 211576_s_at SLC19A1 12.26 9.25E−11 SLC19 (folate transporter), member 1
5 214546_s_at P2RY11 11.89 1.59E−10 Purinergic R P2Y, G-protein coupled, 11
6 206682_at CD301 9.91 3.65E−09 C-type lectin domain family 10, member A
7 207634_at CD279/PD1 9.61 6.20E−09 Programmed cell death 1
8 237273_at KCNU1 9.55 6.82E−09 Potassium channel, subfamily U, member 1
9 206743_s_at ASGR1 9.53 7.04E−09 Asialoglycoprotein receptor 1
10 223278_at GJB2 9.27 1.11E−08 Gap junction protein, beta 2
11 220028_at ACVR2B 9.23 1.20E−08 Activin A receptor, type IIB
12 209589_s_at EPHB2 9.10 1.50E−08 EPH receptor B2
13 219796_s_at CDHR5 9.06 1.62E−08 Cadherin-related family member 5
14 206130_s_at ASGR2 8.83 2.45E−08 Asialoglycoprotein receptor 2
15 224392_s_at OPN3 8.74 2.92E−08 Opsin 3 (encephalopsin, panopsin)
16 219386_s_at CD353 8.53 4.23E−08 SLAM family member 8 (CD353)
17 227281_at SLC29A4 8.44 5.04E−08 SLC29 (nucleoside transporters), member 4
18 1553995_a_at CD73 8.41 5.35E−08 5′-Nucleotidase, ecto
19 211249_at GPR68 8.40 5.42E−08 G protein-coupled receptor 68
20 228844_at SLC13A5 8.33 6.18E−08 SLC13 (Na-dep. citrate transporter), 5
21 213728_at CD107a 8.12 9.28E−08 LAMP1
22 211042_x_at CD146/MCAM 7.99 1.19E−07 Melanoma cell adhesion molecule (MUC18)
23 207565_s_at MR1 7.86 1.53E−07 MHC, class I-related
24 206361_at PTGDR2 7.82 1.65E−07 Prostaglandin D2 receptor 2/CD294
25 219732_at LPPR1/PRG3 7.56 2.79E−07 Lipid phosphate phosphatase-related prot. 1
(Continued)
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NB
1 239913_at SLC10A4 12.60 4.66E−13 SLC10 (Na/bile acid cotransporter family), 4
2 210221_at CHRNA3 9.39 3.75E−10 Cholinergic receptor, nicotinic, alpha 3
3 227281_at SLC29A4 9.02 8.84E−10 SLC29 (nucleoside transporters), member 4
4 205122_at TMEFF1 8.21 6.22E−09 TMEFF1
5 207516_at CHRNB4 8.14 7.39E−09 Cholinergic receptor, nicotinic, beta 4
6 203414_at MMD 7.75 1.93E−08 Monocyte to macrophage different.-assoc.
7 212290_at SLC7A1 7.32 5.77E−08 SLC7 (cationic amino acid transporter), 1
8 218811_at ORAI2 7.14 9.11E−08 ORAI Ca-release-activated Ca-modulator 2
9 221585_at CACNG4 7.07 1.09E−07 Ca-channel, voltage-dep., gamma subunit 4
10 239422_at GPC2 7.01 1.26E−07 Glypican 2 (cerebroglycan)
11 209198_s_at SYT11 6.95 1.46E−07 Synaptotagmin XI
12 206343_s_at NRG1 6.92 1.62E−07 Neuregulin 1
13 226029_at VANGL2 6.65 3.26E−07 Vang-like 2 (van gogh, Drosophila)
14 219491_at LRFN4 6.63 3.42E−07 Leucine rich repeat and fn type III domain,4
15 210353_s_at SLC6A2 6.57 3.97E−07 SLC6 (noradrenalin transporter), member 2
16 219523_s_at ODZ3 6.49 4.96E−07 Odz, odd Oz/ten-m homolog 3 (Drosophila)
17 1553956_at TMEM237 6.42 5.96E−07 ALS2CR4, amyotrophic lateral sclerosis 2CR4
18 1552914_a_at CD276 6.39 6.46E−07 CD276 molecule
19 220798_x_at LPPR3/PRG2 6.31 7.97E−07 Lipid phosphate phosphatase-related pr. 3
20 219152_at PODXL2 6.18 1.14E−06 Podocalyxin-like 2
21 40020_at CELSR3 6.12 1.34E−06 Cadherin, EGF LAG seven-pass G-type R 3
22 206189_at UNC5C 6.12 1.34E−06 Unc-5 homolog C (netrin receptor)
23 223854_at PCDHB10 6.04 1.64E−06 Protocadherin beta 10
24 208118_x_a SLC7A5P2 5.98 1.95E−06 SLC 7, member 5 pseudogene 2/IMAA
25 225832_s_at DAGLBETA 5.86 2.65E−06 Diacylglycerol lipase beta
NBL-MYCNA
1 239913_at SLC10A4 14.03 2.18E−16 SLC10 (Na/bile acid cotransporter family), 4
2 205122_at TMEFF1 13.74 4.15E−16 TMEFF1
3 219152_at PODXL2 13.46 7.85E−16 Podocalyxin-like 2
4 210221_at CHRNA3 13.12 1.74E−15 Cholinergic receptor, nicotinic, alpha 3
5 239422_at GPC2 12.66 5.07E−15 Glypican 2 (cerebroglycan)
6 220798_x_at LPPR3/PRG2 12.58 6.16E−15 Lipid phosphate phosphatase-related pr. 3
7 211042_x_at CD146/MCAM 12.11 1.93E−14 Melanoma cell adhesion molecule (MUC18)
8 209776_s_at SLC19A1 11.23 1.77E−13 SLC19 (folate transporter), member 1
9 210508_s_at KCNQ2 11.11 2.43E−13 K voltage-gated channel, KQT-like, 2
10 203414_at MMD 10.91 4.09E−13 Monocyte to macrophage different.-assoc.
11 219537_x_at DLL3 10.43 1.45E−12 Delta-like 3
12 219438_at NKAIN1 10.41 1.53E−12 Na++/K++ transporting ATPase interacting 1
13 227281_at SLC29A4 10.40 1.55E−12 SLC29 (nucleoside transporters), member 4
14 227690_at GABRB3 10.35 1.80E−12 GABA, A receptor, beta 3
15 226029_at VANGL2 10.09 3.62E−12 Vang-like 2 (van gogh, Drosophila)
16 242782_x_at TMEM198 9.89 6.20E−12 Transmembrane protein 198
17 229276_at IGSF9 9.39 2.46E−11 Immunoglobulin superfamily, member 9
18 1553956_at TMEM237 9.25 3.69E−11 ALS2CR4, amyotrophic lateral sclerosis 2CR4
19 202594_at LEPROTL1 9.13 5.15E−11 Leptin receptor overlapping transcript-like 1
20 212290_at SLC7A1 9.07 6.08E−11 SLC7 (cationic a.a. transporter),1/LAT1-3TM
21 231397_at LPPR5/PRG5 9.03 6.90E−11 PAP2D (phosphatidic acid phosphatase, 2)
22 232263_at SLC6A15 8.98 7.98E−11 SLC6, member 15
23 1552914_a_at CD276 8.94 8.90E−11 CD276 molecule (B7-H3)
24 219491_at LRFN4 8.91 9.76E−11 LRFN4
25 207162_s_at CACNA1B 8.86 1.12E−10 Ca channel, voltage-dep., L type, alpha 1B
(Continued)
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OS
1 202667_s_at SLC39A7 12.57 1.75E−13 SLC39 (zinc transporter), member 7
2 240955_at PANX3 11.06 4.14E−12 Pannexin 3
3 210087_s_at MPZL1 10.96 5.22E−12 Myelin protein zero-like 1
4 212250_at MTDH 10.92 5.69E−12 Metadherin
5 238542_at ULBP2 10.11 3.58E−11 UL16 binding protein 2 (NKG2D)
6 218989_x_at SLC30A5 9.93 5.34E−11 SLC30 (zinc transporter), member 5
7 206328_at CDH15 9.78 7.67E−11 Cadherin 15, M-cadherin (myotubule)
8 209280_at CD280 9.45 1.70E−10 MRC2, mannose receptor, C type 2
9 219330_at VANGL1 9.18 3.21E−10 Vang-like 1 (van gogh, Drosophila)
10 202828_s_at MMP14 9.07 4.21E−10 Matrix metallopeptidase 14
11 239433_at LRRC8E 8.82 7.90E−01 Leucine rich repeat containing, 8E
12 218855_at GPR175 8.67 1.13E−09 TPRA1
13 211042_x_at CD146/MCAM 8.57 1.47E−09 Melanoma cell adhesion molecule (MUC18)
14 225867_at VASN 8.44 2.04E−09 Vasorin
15 204928_s_at SLC10A3 8.34 2.60E−09 SLC10 (Na/bile acid cotransporter fam.), 3
16 206399_x_at CACNA1A 8.20 3.71E−09 Ca channel, voltage-dep. P/Q type, alpha 1A
17 203578_s_at SLC7A6 8.00 6.31E−09 SPC7 (cationic amino acid transporter), 6
18 212662_at CD155 7.98 6.53E−09 Poliovirus receptor
19 208299_at CACNA1I 7.88 8.61E−09 Ca channel, voltage-dep., alpha 1I subunit
20 209030_s_at CADM1/IGSF4A 7.88 8.66E−09 Immunoglobulin superfamily, member 4
21 213909_at LRRC15 7.72 1.29E−08 Leucine rich repeat containing 15
22 205120_s_at SGCB 7.54 2.09E−08 Sarcoglycan, beta
23 220455_at SLC16A8 7.48 2.43E−08 SLC16, member 8
24 211837_s_at PTCRA 7.43 2.77E−08 Pre T-cell antigen receptor alpha
25 239422_at GPC2 7.40 3.00E−08 Glypican 2 (cerebroglycan)
ARMS
1 211042_x_at CD146/MCAM 27.68 2.82E−20 Melanoma cell adhesion molecule (MUC18)
2 206633_at CHRNA1 24.21 7.16E−19 Cholinergic R, nicotinic, alpha 1 (muscle)
3 211237_s_at FGFR4 19.67 1.00E−16 Fibroblast growth factor receptor 4
4 236517_at MEGF10 19.19 1.78E−16 Multiple EGF-like-domains 10
5 205327_s_at ACVR2A 14.78 7.27E−14 Activin A receptor, type IIA
6 205903_s_at KCNN3 14.00 2.46E−13 K intermediate/small conductance, CNN3
7 206328_at CDH15 13.85 3.14E−13 Cadherin 15, M-cadherin (myotubule)
8 224182_x_at SEMA6B 12.15 5.46E−12 Semaphorin 6B
9 239422_at GPC2 11.89 8.69E−12 Glypican 2 (cerebroglycan)
10 205858_at CD271/NGFR 11.43 2.03E−11 NGFR, nerve growth factor receptor
11 208299_at CACNA1I 11.30 2.60E−11 Ca channel, voltage-dep., alpha 1I subunit
12 203510_at MET 11.07 3.97E−11 Met proto-oncogene
13 221408_x_at PCDHB12 10.99 4.65E−11 Protocadherin beta 12
14 219692_at KREMEN2 10.85 6.01E−11 Kringle containing transmembrane protein 2
15 221355_at CHRNG 10.80 6.64E−11 Cholinergic receptor, nicotinic, gamma
16 212157_at CD362/SDC2 10.59 1.00E−10 Syndecan 2
17 211693_at IGHA1 10.43 1.36E−10 Immunoglobulin heavy constant alpha 1
18 212290_at SLC7A1 10.41 1.43E−10 SLC7 (cationic a.a. transp., y++ system), 1
19 211837_s_at PTCRA 10.32 1.70E−10 Pre T-cell antigen receptor alpha
20 207555_s_at TBXA2R 10.29 1.80E−10 Thromboxane A2 receptor
21 230668_at NKAIN4 10.28 1.83E−10 Na++/K++ transporting ATPase interacting 4
22 222596_s_at LGR4 10.01 3.11E−10 Leucine-rich repeat-containing GPCR4
23 206128_at ADRA2C 9.99 3.27E−10 Adrenergic, alpha-2C-, receptor
24 209776_s_at SLC19A1 9.98 3.31E−10 SLC19 (folate transporter), member 1
25 221450_x_at PCDHB13 9.96 3.45E−10 Protocadherin beta 13
(Continued)
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Table 3 | Continued
Affy ID Gene symbol T value P value Gene name
ERMS
1 211042_x_at CD146/MCAM 20.87 5.46E−16 Melanoma cell adhesion molecule (MUC18)
2 206633_at CHRNA1 12.63 1.47E−11 Cholinergic R, nicotinic, alpha 1 (muscle)
3 239422_at GPC2 11.62 7.31E−11 Glypican 2 (cerebroglycan)
4 208299_at CACNA1I 11.07 1.83E−10 Ca channel, voltage-dependent, alpha 1I
5 206328_at CDH15 11.00 2.06E−10 Cadherin 15, M-cadherin (myotubule)
6 224182_x_at SEMA6B 11.00 2.07E−10 Semaphorin 6B
7 236701_at GSG1L 10.62 4.00E−10 GSG1-like (has a PMP22 claudin domain)
8 236186_x_at IL17RE 10.28 7.27E−10 Interleukin 17 receptor E
9 222596_s_at LGR4 10.06 1.08E−09 Leucine-rich repeat-containing GPCR4
10 214555_at SSTR5 9.88 1.51E−09 Somatostatin receptor 5
11 207048_at SLC6A11 9.69 2.14E−09 SLC6 (GABA transporter), member 11
12 236517_at MEGF10 9.58 2.64E−09 Multiple EGF-like-domains 10
13 205327_s_at ACVR2A 9.52 2.92E−09 Activin A receptor, type IIA
14 216680_s_at EPHB4 9.52 2.95E−09 EPH (ephrin) receptor B4
15 237503_at SLC5A8 9.45 3.32E−09 Solute carrier family 5, member 8
16 209769_s_at CD42c 9.40 3.71E−09 GP1BB, glycoprotein Ib, beta polypeptide
17 211693_at IGHA1 9.10 6.57E−09 Immunoglobulin heavy constant alpha 1
18 211837_s_at PTCRA 9.09 6.67E−09 Pre T-cell antigen receptor alpha
19 209280_at CD280 9.08 6.75E−09 MRC2, mannose receptor, C type 2
20 209776_s_at SLC19A1 8.71 1.40E−08 SLC19 (folate transporter), member 1
21 222935_x_at SLC39A8 8.65 1.59E−08 SLC39 (zinc transporter), member 8
22 207927_at HTR7 8.59 1.76E−08 5-Hydroxytryptamine (serotonin) receptor 7
23 214546_s_at P2RY11 8.19 3.96E−08 Purinergic RP2Y, G-protein coupled, 11
24 207555_s_at TBXA2R 8.12 4.56E−08 Thromboxane A2 receptor
25 234724_x_at PCDHB18 7.99 6.03E−08 Protocadherin beta 18 pseudogene
Non_RMS_STS
1 244857_at HBEGF 15.03 5.30E−12 Heparin-binding EGF-like growth factor
2 207555_s_at TBXA2R 14.55 9.40E−12 Thromboxane A2 receptor
3 208338_at P2RX3 14.40 1.13E−11 Purinergic R P2X, ligand-gated ion channel, 3
4 210152_at CD85k/LILRB4 13.51 3.41E−11 Leukocyte Ig-like receptor, subfamily B4
5 211693_at IGHA1 12.80 8.60E−11 Immunoglobulin heavy constant alpha 1
6 206616_s_a ADAM22 12.76 9.07E−11 ADAM metallopeptidase domain 22
7 211909_x_at PTGER3 12.25 1.84E−10 Prostaglandin E receptor 3 (subtype EP3)
8 214546_s_at P2RY11 12.01 2.57E−10 Purinergic R P2Y, G-protein coupled, 11
9 233171_at GRIN3A 11.77 3.57E−10 Glutamate receptor, ionotropic, NMDA 3A
10 219516_at TRPV4 11.57 4.76E−10 Transient R potential cation channel, V4
11 234756_at CACNG8 11.49 5.41E−10 Ca channel, voltage-dep., gamma subunit 8
12 1554728_at SLC9A1 11.35 6.55E−10 SLC9 (Na/H exchanger), member 1
13 206729_at CD30 11.13 9.07E−10 (TNFRSF8, Ki-1)
14 216734_s_at CD185 11.03 1.07E−09 CXCR5
15 207927_at HTR7 11.02 1.07E−09 5-Hydroxytryptamine (serotonin) receptor 7
16 208401_s_at GLP1R 10.99 1.13E−09 Glucagon-like peptide 1 receptor
17 233968_at CST11 10.96 1.17E−09 Cystatin 11
18 232846_s_at CDH23 10.88 1.34E−09 Cadherin-like 23
19 233913_at WFDC10A 10.71 1.73E−09 WAP four-disulfide core domain 10A
20 207048_at SLC6A11 10.65 1.89E−09 SLC6 (GABA transporter), member 11
21 1567238_at OR2L2 10.37 2.92E−09 Olfactory R, family 2, subfamily L, member 2
22 221061_at PKD2L1 10.33 3.10E−09 Polycystic kidney disease 2-like 1
23 244617_at GPR26 10.18 3.93E−09 G protein-coupled receptor 26
24 216873_s_at ATP8B2 10.02 5.14E−09 ATPase, Class I, type 8B, member 2
25 211399_at FGFR2 9.83 6.88E−09 Fibroblast growth factor receptor 2
Antigens identified inTable 2 were grouped according to functional activity (CD antigens/markers, cell adhesion or cell junction, enzymatic function, growth factor
or developmental factor receptor, neurotransmitter receptor, ion channel protein or ion channel regulator, SLC, solute carrier family member, G-protein or G-protein
associated, migration or metastasis or cell motility function, tetraspanins, or uncharacterized) in order to give an overview of target types.
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FIGURE 2 | Frequency of hits across disease category. Transcripts
appearing in the pediatric Top 25 were often shared between disease
types. All of the transcripts expressed in more than three (A), or at least
three (B), cancer types are listed. The x -axis lists the individual gene, and
the stacked boxes represent presence of that transcript in the Top 25 for
that disease type.
Aberrant expression of these family members has been described
in colon carcinoma (Herath et al., 2012). EPHB4 plays a role in vas-
cular development and may participate in tumor metastatic spread
(Heroult et al., 2010). Antibodies to EphB4 have been described
to inhibit tumor growth (Krasnoperov et al., 2010). Both activin
and ephrin receptors are promising for further investigation as cell
surface targets in pediatric solid tumors.
Fibroblast growth factor receptors (FGFRs) are of great inter-
est in pediatric oncology, and our bioinformatic hit for FGFR4 in
ARMS confirms our previous genomic studies. There are 4 FGFRs
that mediate cellular activation by the more than 20 known fibrob-
last growth factors (Olsen et al., 2003). Alterations or mutation
of the FGFRs have been described in a number of cancer types,
and they have been proposed as targets for both kinase inhibitor
chemotherapy as well as immunotherapy (Wesche et al., 2011).
Our group had previously identified FGFR4 as a target in rhab-
domyosarcoma using gene expression array analysis and we have
demonstrated FGFR4 activity in disease (Taylor et al., 2009). The
closely related FGFR2 was also identified as a hit in STS and GBM.
FGFR2 has been associated with a number of cancers making both
of these FGFRs exciting findings for pediatric oncology (Bai et al.,
2010).
DISEASE-SPECIFIC OBSERVATIONS
The most intriguing hit for Non-Rhabdomyosarcoma STS is
CD30 (TNFRSF8). CD30 is the current target of a number
of immunotherapy trials, and our report suggests that these
reagents should be evaluated for use in STS (Kasamon and
Ambinder, 2008). In DSRCT we find expression of two very
exciting hits, poliovirus receptor (PVR)/CD115 and PVR-related
2 (PVRL2)/CD112. Both these adhesion molecules have been
described as NK-ligands and should serve as suitable immune
targets (Pende et al., 2005). An equally exciting target on DSRCT
is PDCD1 (PD1/CD279). The antigen is well-described as an anti-
immune effector and efforts to block or target PD1 in cancer are
actively underway (Flies et al., 2011).
The immune markers expressed EWS represent a unique group
of targets. XG, is part of the Xg blood group antigen, the only
other member of which is CD99, a well-known over-expressed
protein in EWS, and expression of these antigens is closely linked
(Johnson, 2011). Although transcripts are known to be found
in non-erythroid tissues not much else is known for this target
(Fouchet et al., 2000). Meynet et al. (2010), have also recently
described XG as a marker for EWS and demonstrate that its expres-
sion is associated with poor outcome. Three cytokine receptors
are expressed on EWS: IL17RE, IL27RA, and IL1RAP. A recent
mutational study demonstrated that IL27RA has transforming
potential, although its expression on non-lymphoid malignan-
cies has not previously been described (Lambert et al., 2011).
IL1RAP, Interleukin-1 receptor accessory protein, can exist as a
membrane or soluble form and is essential for IL-1 receptor activ-
ity. Expression of IL1RAP has been described in endometriosis and
various leukemias, notably in leukemia stem cells, making IL1RAP
a high-value target for EWS (Jaras et al., 2010; Guay et al., 2011).
Glioblastoma expresses the immune markers in CD73/NT5E
(5′ nucleotidase, ecto), and CKLF. CD73 is present on cancer exo-
somes and has been shown to blunt immune responses (Clayton
et al., 2011). CD73 is also a hit for HBL. CKLF, chemokine-like fac-
tor 1, binds CCR4 and can be either secreted or membrane-bound
and contains a MARVEL transmembrane domain (Chowdhury
et al., 2008). MARVELD2 is a transmembrane protein associ-
ated with tight junction that serves as a hit for HBL. The wide
distribution of these targets requires more developmental work
before considering using them as immune targets. GALR2, galanin
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receptor 2, is a growth factor receptor that also is an interesting
GBM target. GALR2 has been proposed as a therapeutic target in
head and neck carcinoma and is an active area of study (Kanazawa
et al., 2010). GAL2R targeting should be explored in GBM as well.
Osteosarcoma expresses the intriguing hit UL16 binding pro-
tein 2 (ULBP2), which is a ligand for the NK cell activation marker
NKGD2. To date, ULBP2 has been thought of as a means to
alert to immune system due to p53 activation on target cells, and
not as a mean of cancer immune escape (Textor et al., 2011).
The matrix metalloproteinase MMP14 is known to participate in
tumor metastasis and is the subject of intense research activity,
making this a high-value target in OS and ASPS (Zarrabi et al.,
2011). VASN, vasorin, is a transforming growth factor beta (TGF-
β) trap, its biology is regulated by ADAM17, and it appears to play
a role in epithelial to mesenchymal transition in other cancer types
(Malapeira et al., 2011). Both of these two OS surface targets may
play a role in disease progression.
In the analysis of MYCN-Amplified Neuroblastoma (NBL-
MYCNA) our algorithm identified one of the most interesting
current targets, CD276 (B7-H3). CD276 is the target of a num-
ber of immune directed therapies in NBL (Castriconi et al., 2004).
The other targets identified for NML-MYCNA and for NB are all
of great interest, but CD276 is likely to be a focus of future immune
based strategies.
Hepatoblastoma overexpresses ASGR1 asialoglycoprotein
receptor 1, and ASGR2. ASGR2 serves as a receptor for a series
of glycoproteins including those on the surface of hepatitis virus
(Yang et al., 2010). The only report of association with cancer is
the reported increase in the rate of cell division of colorectal car-
cinoma cell lines when grown on ASGR1 coated surfaces, which
makes both ASGRs intriguing hits (Fang et al., 2009). Another
potential target for HBL is MR1, MHC class I-related, which is
also expressed in ASPS. MR1 is an invariant class I MHC mol-
ecule known to interact with a subset of T lymphocytes with
invariant or restricted TCRs (Gozalbo-Lopez et al., 2009). The
expression of MR1 in cancer has not been reported, making this
a novel finding. CD301 (CLEC10A, C-type lectin domain family
10, member A) has not been reported in cancer either, but like
any adhesion receptor it has the potential to mediate metastasis.
Another adhesion receptor hit is CD353, SLAMF8 [signal lym-
phocyte activation molecule (SLAM), family member 8]. SLAM
proteins are in the CD2 family of lymphocyte activation proteins
and may also contribute to the activation of cancer cells (Furukawa
et al., 2010).
ALVEOLAR SOFT PART SARCOMA
ASPS is a very distinct entity as evidenced by the unique set of
antigens we report as top 25 hits, many of which are not shared
with other tumors. EPOR, the erythropoietin receptor, was the
highest-ranking hit for ASPS. The ETV6-RUNX1 fusion in ALL
activates transcription of EPOR and it is likely to contribute a
growth signal to leukemia, making this a potential target of inter-
est (Torrano et al., 2011). Two CD antigens that were strong hits for
ASPS are also growth factor receptors. Colony-stimulating factor
1/CD115 (CSF1R) modulates a number of myeloid differentia-
tion steps and inhibitors have been designed for a number of
disease states (Hume and Macdonald, 2012). CD222/ insulin-like
growth factor-2 (IGF2R) has long been recognized as a cancer-
expressed protein (Martin-Kleiner and Gall Troselj, 2010). Each
of these receptors should be explored as targets in ASPS. Also
intriguing is the expression of HLA-G. HLA-G is a class I MHC
paralog, normally expressed on placental cells, and its expression
has been described on malignant cells, perhaps shielding them
from immunosurveillance (Yan, 2011). CD204/macrophage scav-
enger receptor 1 (MSR1) is another immune molecule expressed
on ASPS. Expression of CD204 on tumor stromal macrophages has
been associated with aggressiveness in lung cancer (Ohtaki et al.,
2010). Thus ASPS provides a number of CD or CD-like antigens
that can be targeted by means of immunotherapy.
DISCUSSION
How a cell surface antigen expressed on a tumor becomes a locus
of tumor-protective immune activation, and how this response
spares healthy tissue has yet to be fully defined. An antigen may
be “revealed” by inhibiting immune checkpoints, or newly recog-
nized as an antigenic target by vaccination (such as with PMSA;
May et al., 2011). The key for both approaches is that a response
has been induced that now sufficiently differentiates between can-
cer and normal host tissue. What “sufficient differentiation” is,
remains a term in need of clarification. For example, some self-
antigens, such as CD20, can readily be targeted, while others,
such as HER2, are highly dependent on how they are targeted.
The mature B cells compartment is apparently dispensable, as use
of anti-CD20 antibody in lymphoma therapy has demonstrated.
Once the B cell compartment is no longer targeted by the therapy,
the B cell population is then replenished. HER2 (Neu, CD340,
ErbB-2) has been effectively targeted in thousands of women
with breast cancer using anti-HER2 antibody. However, admin-
istration of a T-cell population expressing a HER2-specific CAR
resulted in treatment related mortality. In this special instance a
large number of anti-HER-2-CAR engineered T-cells presumably
bound to the low levels of HER2 present in the lung, and a mas-
sive cytokine storm ensued leading to death (Morgan et al., 2010).
This event clearly shows that “how” a tumor antigen is targeted
by the immune system may be as important as the expression
level of that antigen on various tissues. It also illustrates that we
have yet to create a universal definition of whether or not it is
safe to target a tumor antigen expressed at very low levels on
normal tissue. Targeting B cell malignancies has worked so well
because the mature B cell compartment that expresses CD20 and
CD19 is expendable (Biagi et al., 2007). A database that would
begin to define what an “expendable” normal tissue is would be
ideal. However, we have yet to even clearly formulate this ques-
tion with regard to a specific bioinformatic search algorithm. For
pediatric cancers, the issue is even more concerning, as certain
growth factor receptors may be present on normal tissue that are
crucial to development, and would not be part of the “normal”
gene expression signature, if it was defined by specimens from
adult tissues. Before proceeding with targeting any of the antigens
we have identified in this report, we must both confirm expres-
sion on tumor and more importantly, confirm as best as we can
the lack of expression on “non-expendable” tissues. In this report
we identified the major pediatric tumor-associated antigens that
are expressed on the plasma membrane, as defined by standard
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gene chip analysis, statistical analysis, and filtering of annotated
attributes. The strength of gene expression profiling is its util-
ity in differential analysis (comparisons of transcript expression
in different samples or comparison of tumor versus normal tis-
sue). One potential drawback is that gene chip technology may
be skewed, in some instances, toward identification of 3′ tran-
scripts, and thus tumor-specific splice variations or deletions may
be missed. Nevertheless studies, including our own, have shown
a significant correlation between mRNA and protein levels (Chen
et al., 2010). The Affymetrix plus2 array used here attempts to
capture multiple independent measurements for each transcript
and therefore measures expression of the major transcript as well
as other splice variants. However a better more precise but not
yet perfect measurement of the expression levels of each tran-
script is afforded by next generation technologies, e.g., whole RNA
sequencing (RNAseq). We are pursuing these measurements, but
until complete RNASeq is available for the major pediatric tumor
types, along with normal tissue, our approach remains current.
Validation with antibody or ligand-based staining for receptors in
tumor normal tissues will be needed to definitively credential each
candidate transcript.
Ultimately, we plan to continue to refine our definition of which
membrane proteins can be safely targeted by CAR or antibody-
based therapies, as new analysis techniques emerge. We propose
that given the breadth of the antigen list presented here, that a
large-scale effort be made to systematically evaluate cell surface
targets on pediatric tumors for their potential for immunother-
apy. Specifically, antibodies or scFv binding fragments for these
antigens need to be screened in a large-scale manner for reactivity
to normal tissues. The small size of the overall market in pediatric
oncology for these reagents makes it unlikely that industry will
engage in this approach on its own. However, given the wealth of
genomic and proteomic data being generated, academia can take
advantage of these findings and translate them into reagents that
can be tested in pre-clinical settings. The analysis framework we
present here may also inspire a new look at common adult malig-
nancies, and encourage the development of a new generation of
broad-based approaches for identifying immunotherapy targets.
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